NuTide:302: A phase Ib study to assess the safety, pharmacokinetics and clinical activity of the ProTide NUC-3373 when combined with standard agents used in colorectal cancer.T.R. Jeffry Evans, Jordan Berlin, Aimery de Gramont et al.|Journal of Clinical Oncology|2019Cited by 7
Abstract C059: Inhibition of thymidylate synthase by the ProTide NUC-3373: <i>in vitro</i> analysis and clinical validationSarah P. Blagden, David J. Harrison, Fiona G. McKissock et al.|Molecular Cancer Therapeutics|2019Cited by 1